Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $138.90M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 3.91M
Average 8.14M
HUMA Operating Cash Flow
Cash generated by the company's core business operations during the period.
Humacyte, Inc.NASDAQ: HUMA
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow dips below year-ago levels
Q1 FY2026 operating cash flow of $25.1M (cash outflow) fell 12.2% year over year, behind the +2.2% change in trailing-twelve-month operating cash flow. Sequentially, it fell 3.9% from the prior quarter. Over 3 fiscal years it compounded at +13.9% a year.
Context
- Operating cash flow amounted to 5154.2% of revenue in FY2025.
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -12.2% toward the trailing-twelve-month pace of +2.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (105.04M) USD
- Year-over-year change
- -7.1%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (105.04M) | -7.1% |
| FY2024 | 2024-12-31 | (98.12M) | -33.9% |
| FY2023 | 2023-12-31 | (73.31M) | -3.1% |
| FY2022 | 2022-12-31 | (71.13M) | +12.4% |
| FY2021 | 2021-12-31 | (81.19M) | — |
Operating Cash Flow vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 operating cash flow of $101.54M is the 5th largest of the 11 companies compared; the peer median is $72.99M.
- Its year-over-year change of +2.2% is the 6th highest of 11, against a peer median of +3.5%.
- Operating cash flow amounts to 5037.0% of revenue for HUMA, versus a peer median of 309.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $147.86M | +17.2% | +3.0% | — | |
| LTM Mar 2026 | $131.7M | +141.5% | +11.1% | 2295.2% | |
| LTM Mar 2026 | $127.99M | +14.3% | +119.6% | 350.7% | |
| LTM Mar 2026 | $126.51M | +124.0% | — | 58.1% | |
| LTM Mar 2026 | $101.54M | +2.2% | +13.9% | 5037.0% | |
| LTM Mar 2026 | $87.4M | -8.0% | — | 309.7% | |
| LTM Mar 2026 | $58.57M | -34.4% | — | 129.2% | |
| LTM Mar 2026 | $49.86M | -12.2% | +3.4% | — | |
| LTM Mar 2026 | $49.7M | -7.3% | +0.9% | — | |
| LTM Mar 2026 | $45.31M | +27.4% | +9.6% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $39.73M | -21.7% | +23.1% | — |
| Peer median (excluding HUMA) | $72.99M | +3.5% | +9.6% | 309.7% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 5.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.15M | 6.18M | 6.83M | 6.14M | 9.75M |
| Change in Working Capital | (557K) | 1.03M | 6.57M | 311K | (23.4M) |
| Accounts Receivables | (63K) | 145K | 31K | 0 | (261K) |
| Inventory | 0 | 0 | 0 | 0 | (21.83M) |
| Accounts Payables | (197K) | (509K) | 4.81M | (1.96M) | 973K |
| Other Working Capital | (297K) | 1.39M | 1.73M | 2.27M | (2.28M) |
| Other Non-Cash Items | (72.54M) | (74.59M) | 16.35M | 36.94M | (55.9M) |
| Operating Cash Flow | (81.19M) | (71.13M) | (73.31M) | (98.12M) | (105.04M) |
| Capital Expenditures | (220K) | (1.05M) | (2.28M) | (1.57M) | (884K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (8M) | (10.11M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 16M | 2.11M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (8.22M) | 4.85M | (173K) | (1.57M) | (884K) |
| Debt Repayment | 27.93M | (1.98M) | 5.7M | (2.58M) | 36.39M |
| Common Stock Issued | 598K | 535K | 566K | 45.93M | 113.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 239.05M | 535K | (1.76M) | 27.71M | (88.34M) |
| Financing Cash Flow | 266.98M | (1.45M) | 4.51M | 114.18M | 61.49M |
| Effect of Forex Changes | 0 | 0 | (209K) | 0 | 0 |
| Net Change in Cash | 177.57M | (67.73M) | (69.18M) | 14.49M | (44.44M) |
| Free Cash Flow | (81.41M) | (72.18M) | (75.59M) | (99.69M) | (105.93M) |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.